Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1998 3
1999 2
2000 4
2002 1
2006 1
2007 1
2008 3
2009 1
2011 2
2012 1
2014 1
2015 2
2016 1
2018 1
2019 1
2020 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
["Lean management" in hospitals: potentials and limitations].
Glossmann JP, Schliebusch O, Diehl V, Walshe R. Glossmann JP, et al. Among authors: walshe r. Med Klin (Munich). 2000 Aug 15;95(8):470-3. doi: 10.1007/s000630050011. Med Klin (Munich). 2000. PMID: 10985072 Review. German.
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G. Müller D, et al. Among authors: walshe r. Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20. Leuk Lymphoma. 2016. PMID: 26584689
Cost of illness of malignant lymphoma in Germany.
Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R. Reis A, et al. Among authors: walshe r. Eur J Cancer Care (Engl). 2006 Sep;15(4):379-85. doi: 10.1111/j.1365-2354.2006.00676.x. Eur J Cancer Care (Engl). 2006. PMID: 16968321
25 results